GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aptorum Group Ltd (NAS:APM) » Definitions » Notes Receivable

Aptorum Group (Aptorum Group) Notes Receivable : $0.00 Mil (As of Jun. 2023)


View and export this data going back to 2018. Start your Free Trial

What is Aptorum Group Notes Receivable?

Aptorum Group's Notes Receivable for the quarter that ended in Jun. 2023 was $0.00 Mil.


Aptorum Group Notes Receivable Historical Data

The historical data trend for Aptorum Group's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aptorum Group Notes Receivable Chart

Aptorum Group Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Notes Receivable
Get a 7-Day Free Trial - - - - -

Aptorum Group Semi-Annual Data
Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Aptorum Group Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.


Aptorum Group Notes Receivable Related Terms

Thank you for viewing the detailed overview of Aptorum Group's Notes Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Aptorum Group (Aptorum Group) Business Description

Traded in Other Exchanges
N/A
Address
17 Hanover Square, London, GBR, W1S 1BN
Aptorum Group Ltd clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The company operates in two segments: Therapeutics and Non-Therapeutics. The projects are ALS-4, SACT-1, and RPIDD. It is also engaged in providing healthcare services.

Aptorum Group (Aptorum Group) Headlines

From GuruFocus

Aptorum Group Announces Offering of $3 Million Convertible Note due 2023

By Business Wire Business Wire 12-09-2022

Aptorum Group Limited Announces Voluntary Delisting from Euronext Paris

By Business Wire Business Wire 06-09-2023